Structure via PubChem · Public domain (PubChem)
dolutegravir
Sign in to saveAlso known as GSK 1349572, GSK-1349572, GSK1349572, S-349572, S/GSK1349572
Dolutegravir (DTG), sold under the brand name Tivicay or Instgra, is an antiretroviral medication used, together with other medication, to treat HIV/AIDS. It may also be used, as part of post exposure prophylaxis, to prevent HIV infection following potential exposure. It is taken by mouth.
Chemical data
- Formula
- C20H19F2N3O5
- Molecular weight
- 419.4 g/mol
- IUPAC name
- (3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.03,8]tetradeca-10,13-diene-13-carboxamide
- SMILES
- C[C@@H]1CCO[C@@H]2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O
- InChIKey
- RHWKPHLQXYSBKR-BMIGLBTASA-N
- XLogP
- 2.4
- Polar surface area
- 99.2 Ų
- H-bond donors
- 2
- H-bond acceptors
- 8
- Formal charge
- 0
via PubChem
Research
3,167 papers- Dolutegravir-associated hyperglycemia: a narrative review.AIDS research and therapy · 2025
- HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis.The lancet. HIV · 2023
- Dolutegravir/Lamivudine Single-Tablet Regimen: A Review in HIV-1 Infection.Drugs · 2020
- Predictors of treatment-emergent resistance to dolutegravir.The lancet. HIV · 2025
- Dolutegravir/Rilpivirine: A Review in HIV-1 Infection.Drugs · 2018
via PubMed
~6 min read
Encyclopedic overview
7 sectionsContents
- Medical use
- Adverse effects
- Pregnancy
- History
- Access
- Climate change
- References
Dolutegravir (DTG), sold under the brand name Tivicay or Instgra, is an antiretroviral medication used, together with other medication, to treat HIV/AIDS. It may also be used, as part of post exposure prophylaxis, to prevent HIV infection following potential exposure. It is taken by mouth.
Common side effects include trouble sleeping, feeling tired, diarrhea, high blood sugar, and headache. Severe side effects may include allergic reactions and liver problems. Concerns that usage during pregnancy can result in harm to the baby have been refuted by further studies that show there is no statistical difference in neural tube defects from the usage of dolutegravir compared to other antiretrovirals. It is unclear if use during breastfeeding is safe. Dolutegravir is an HIV integrase strand transfer inhibitor which blocks the functioning of HIV integrase which is needed for viral replication.
Excerpted from Wikipedia’s “dolutegravir” article, available under the CC BY-SA 4.0 licence.